Tag: NGNE

Neurogene has achieved a major breakthrough in its clinical trial for gene therapy targeting Rett syndrome. The company recently announced ...

On January 17, 2024, Mitchell Kapoor, an analyst at HC Wainwright & Co., expressed a favorable stance on Neurogene (NASDAQ:NGNE), ...